<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">8050732</PMID>
      <DateCompleted>
        <Year>1994</Year>
        <Month>09</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>02</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0378-7346</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>37</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>1994</Year>
            </PubDate>
          </JournalIssue>
          <Title>Gynecologic and obstetric investigation</Title>
          <ISOAbbreviation>Gynecol Obstet Invest</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Nafarelin in the treatment of endometriosis. Dose management.</ArticleTitle>
        <Pagination>
          <StartPage>263</StartPage>
          <EndPage>264</EndPage>
          <MedlinePgn>263-4</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Nafarelin, a gonadotropin-releasing hormone agonist, has been shown to be effective in the treatment of endometriosis. The standard dosage is 200 micrograms bid intranasally. Side effects most commonly include those associated with estrogen deprivation. By assessing estrogen status, the standard dosage can be manipulated to minimize these side effects and increase patient compliance.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hull</LastName>
            <ForeName>M E</ForeName>
            <Initials>ME</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, SUNY at Stony Brook 11794.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barbieri</LastName>
            <ForeName>R L</ForeName>
            <Initials>RL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Gynecol Obstet Invest</MedlineTA>
        <NlmUniqueID>7900587</NlmUniqueID>
        <ISSNLinking>0378-7346</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>1X0094V6JV</RegistryNumber>
          <NameOfSubstance UI="D017274">Nafarelin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4TI98Z838E</RegistryNumber>
          <NameOfSubstance UI="D004958">Estradiol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000698" MajorTopicYN="N">Analgesia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004715" MajorTopicYN="N">Endometriosis</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017274" MajorTopicYN="N">Nafarelin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017699" MajorTopicYN="N">Pelvic Pain</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014592" MajorTopicYN="N">Uterine Hemorrhage</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1994</Year>
          <Month>1</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1994</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1994</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">8050732</ArticleId>
        <ArticleId IdType="doi">10.1159/000292574</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
